恶性黑色素瘤PET分子影像探针的研究进展
Advances in PET molecular imaging probes for malignant melanoma
薛岩 1王玲 1黄志洪 1朱雪 1王柯1
作者信息
- 1. 南京医科大学药学院核药学系,江苏 南京 211166;国家卫生健康委员会核医学重点实验室,江苏省分子核医学重点实验室,江苏省原子医学研究所,江苏 无锡 214063
- 折叠
摘要
恶性黑色素瘤是一种侵袭性强且预后不良的肿瘤类型,其预后和疗效很大程度上取决于诊断时疾病的临床分期.PET/CT是一种放射性核素示踪医学影像技术,利用癌细胞的特异性标志来获取有关肿瘤的信息,用于区分肿瘤组织和正常组织.18F-FDG PET已广泛应用于肿瘤原发及转移灶的显像,然而其对恶性黑色素瘤的微小转移灶和非代谢活性病灶的检出率低且其为泛肿瘤探针.进一步开发新型的恶性黑色素瘤特异性PET分子影像探针仍然具有较高的临床价值.本文基于恶性黑色素瘤的发生率、预后信息及诊疗现状,对现有报道的恶性黑色素瘤新型PET分子影像探针的研究进展做一综述.
Abstract
Malignant melanoma is an aggressive tumor type with a poor prognosis. The prognosis and treatment outcome largely depend on the clinical stage of the disease at the time of diagnosis. PET/CT is a medical imaging technique that uses radionuclide tracers to identify specific markers of cancer cells and gather information about the tumor. It is used to differentiate between tumor tissue and normal tissue. Although 18F-FDG PET has been widely used to for imaging of primary and metastatic tumor foci, which still has limitations on the detection of microscopic metastases and non-metabolically active lesions in malignant melanoma as a pan-tumor tracer. Therefore, further development of the novel PET molecular imaging probes to improve the detection rate and diagnostic accuracy of malignant melanoma is still of high clinical value. Based on the incidence of malignant melanoma, prognostic information and the current status of diagnosis and treatment, this paper reviews the progress of existing novel PET molecular imaging probes for early diagnosis and clinical staging of malignant melanoma.
关键词
恶性黑色素瘤/PET/分子影像探针/黑色素/黑皮质素-1受体Key words
malignant melanoma/PET/molecular imaging probe/melanin/melanocortin-1 receptor引用本文复制引用
基金项目
江苏省中医药科技发展计划项目(MS20231662024-2026)
江苏省卫生健康委科研项目(H2023150)
无锡市卫生健康委科研项目(Z2023032024-2025)
出版年
2024
国家科技期刊平台
NSTL
万方数据